Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus | 3 | 2024 | 539 | 0.410 |
Why?
|
| Risk Assessment | 1 | 2016 | 863 | 0.390 |
Why?
|
| Mass Screening | 2 | 2021 | 541 | 0.390 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 760 | 0.380 |
Why?
|
| Peptides | 2 | 2026 | 372 | 0.370 |
Why?
|
| Vimentin | 1 | 2025 | 44 | 0.230 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2025 | 57 | 0.230 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2025 | 59 | 0.220 |
Why?
|
| Hospitals, Public | 1 | 2024 | 14 | 0.220 |
Why?
|
| Cardiovascular Diseases | 2 | 2021 | 749 | 0.210 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2024 | 89 | 0.200 |
Why?
|
| Internship and Residency | 2 | 2024 | 146 | 0.200 |
Why?
|
| Prediabetic State | 1 | 2024 | 69 | 0.200 |
Why?
|
| Vitamin D Deficiency | 1 | 2024 | 107 | 0.200 |
Why?
|
| Masks | 1 | 2023 | 16 | 0.200 |
Why?
|
| Risk Factors | 6 | 2024 | 3994 | 0.190 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2023 | 67 | 0.190 |
Why?
|
| Staphylococcal Infections | 1 | 2023 | 67 | 0.190 |
Why?
|
| Trauma Centers | 1 | 2022 | 92 | 0.180 |
Why?
|
| Coronary Vessels | 1 | 2021 | 92 | 0.170 |
Why?
|
| Lead Poisoning | 1 | 2021 | 25 | 0.170 |
Why?
|
| Burnout, Professional | 1 | 2021 | 31 | 0.170 |
Why?
|
| Adult | 10 | 2024 | 13872 | 0.170 |
Why?
|
| Inflammation | 1 | 2026 | 758 | 0.160 |
Why?
|
| Humans | 18 | 2026 | 43102 | 0.160 |
Why?
|
| Colonic Neoplasms | 1 | 2022 | 223 | 0.160 |
Why?
|
| Postoperative Complications | 1 | 2022 | 263 | 0.160 |
Why?
|
| Lead | 1 | 2021 | 100 | 0.160 |
Why?
|
| MicroRNAs | 1 | 2026 | 518 | 0.160 |
Why?
|
| Female | 11 | 2026 | 24698 | 0.140 |
Why?
|
| Telemedicine | 1 | 2021 | 234 | 0.130 |
Why?
|
| Administrative Personnel | 1 | 2017 | 11 | 0.130 |
Why?
|
| Young Adult | 4 | 2024 | 5080 | 0.130 |
Why?
|
| Area Under Curve | 1 | 2016 | 95 | 0.120 |
Why?
|
| ROC Curve | 1 | 2016 | 159 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2017 | 178 | 0.120 |
Why?
|
| Propensity Score | 2 | 2024 | 59 | 0.110 |
Why?
|
| Blood Glucose | 1 | 2016 | 389 | 0.110 |
Why?
|
| Inservice Training | 1 | 2014 | 33 | 0.110 |
Why?
|
| Male | 7 | 2024 | 23409 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2025 | 1723 | 0.100 |
Why?
|
| Indians, North American | 1 | 2016 | 192 | 0.100 |
Why?
|
| Logistic Models | 1 | 2016 | 1009 | 0.100 |
Why?
|
| Chlamydiaceae Infections | 1 | 2012 | 3 | 0.100 |
Why?
|
| Calcitriol | 1 | 2012 | 32 | 0.100 |
Why?
|
| Receptors, Calcitriol | 1 | 2012 | 69 | 0.090 |
Why?
|
| Chlamydia muridarum | 1 | 2012 | 104 | 0.090 |
Why?
|
| Retrospective Studies | 3 | 2024 | 2544 | 0.090 |
Why?
|
| Georgia | 2 | 2023 | 192 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2026 | 2676 | 0.090 |
Why?
|
| Health Education | 1 | 2014 | 363 | 0.080 |
Why?
|
| Incidence | 2 | 2024 | 1078 | 0.080 |
Why?
|
| Child | 3 | 2023 | 3443 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2024 | 1759 | 0.070 |
Why?
|
| HIV Infections | 1 | 2022 | 2586 | 0.070 |
Why?
|
| Middle Aged | 4 | 2024 | 12222 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 989 | 0.060 |
Why?
|
| Surface Plasmon Resonance | 1 | 2025 | 42 | 0.060 |
Why?
|
| Aged | 3 | 2024 | 8214 | 0.060 |
Why?
|
| Adolescent | 1 | 2016 | 6081 | 0.060 |
Why?
|
| Hospitals, Urban | 1 | 2024 | 42 | 0.050 |
Why?
|
| Mississippi | 1 | 2024 | 129 | 0.050 |
Why?
|
| Infertility | 1 | 2024 | 21 | 0.050 |
Why?
|
| Cause of Death | 1 | 2024 | 186 | 0.050 |
Why?
|
| Binding Sites | 1 | 2025 | 671 | 0.050 |
Why?
|
| Southeastern United States | 1 | 2023 | 64 | 0.050 |
Why?
|
| Medically Underserved Area | 1 | 2024 | 120 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2024 | 263 | 0.050 |
Why?
|
| Vitamin D | 1 | 2024 | 196 | 0.050 |
Why?
|
| Staphylococcus aureus | 1 | 2023 | 94 | 0.050 |
Why?
|
| Cytokines | 1 | 2026 | 678 | 0.050 |
Why?
|
| Protein Binding | 1 | 2025 | 1082 | 0.040 |
Why?
|
| Censuses | 1 | 2021 | 28 | 0.040 |
Why?
|
| Laboratories | 1 | 2021 | 40 | 0.040 |
Why?
|
| Schools | 1 | 2023 | 283 | 0.040 |
Why?
|
| United States | 2 | 2024 | 5205 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2026 | 968 | 0.040 |
Why?
|
| Prevalence | 1 | 2024 | 1612 | 0.040 |
Why?
|
| Insulin | 1 | 2021 | 258 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 706 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2021 | 256 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2021 | 363 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1063 | 0.030 |
Why?
|
| Infant | 1 | 2021 | 1175 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 179 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 3156 | 0.030 |
Why?
|
| Exercise | 1 | 2021 | 692 | 0.030 |
Why?
|
| Health Policy | 1 | 2017 | 184 | 0.030 |
Why?
|
| Focus Groups | 1 | 2017 | 423 | 0.030 |
Why?
|
| Problem Solving | 1 | 2014 | 38 | 0.030 |
Why?
|
| Leadership | 1 | 2014 | 86 | 0.030 |
Why?
|
| Leukocyte Elastase | 1 | 2012 | 12 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2014 | 112 | 0.020 |
Why?
|
| Peer Group | 1 | 2014 | 177 | 0.020 |
Why?
|
| Serpins | 1 | 2012 | 27 | 0.020 |
Why?
|
| Internet | 1 | 2014 | 236 | 0.020 |
Why?
|
| Hela Cells | 1 | 2012 | 376 | 0.020 |
Why?
|
| Proteome | 1 | 2012 | 152 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 1035 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 1070 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 1869 | 0.020 |
Why?
|
| Mice | 1 | 2012 | 6644 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 16992 | 0.010 |
Why?
|